Ascrinvacumab
From Wikipedia, the free encyclopedia
This is an old revision of this page, as edited by Ffffrr (talk | contribs) at 01:11, 26 April 2022 (Importing Wikidata short description: "Chemical compound" (Shortdesc helper)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 01:11, 26 April 2022 by Ffffrr (talk | contribs) (Importing Wikidata short description: "Chemical compound" (Shortdesc helper))
Chemical compound
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Human |
| Target | activin receptor-like kinase 1 |
| Clinical data | |
| Other names | PF-03446962 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6396H9850N1694O2012S44 |
| Molar mass | 144079.64 g·mol−1 |
Ascrinvacumab (PF-03446962) is a monoclonal antibody designed for the treatment of cancer.[1]
This drug was developed by Pfizer Inc.
References
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Bone |
| ||||||||
| Musculoskeletal |
| ||||||||
| Circulatory |
| ||||||||
| Neurologic |
| ||||||||
| Angiogenesis inhibitor |
| ||||||||
| Growth factor |
| ||||||||
| |||||||||
| Type I |
| ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Type II |
| ||||||||||||||
| Type III |
| ||||||||||||||
| Unsorted |
| ||||||||||||||
Hidden categories:
- Articles with short description
- Short description matches Wikidata
- Chemicals that do not have a ChemSpider ID assigned
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without InChI source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Drugs that are a monoclonal antibody
- All stub articles